基因重组干扰素治疗急性乙型肝炎疗效观察  

A report of recombinant interferon α therapy in 19 patients with acute hepatitis B

作　　者：李兴旺[1] 崔振宇[1] 张福杰[1] 丁静秋[1] 

机构地区：[1]北京市地坛医院,100011

出　　处：《中华实验和临床病毒学杂志》1999年第3期295-297,共3页Chinese Journal of Experimental and Clinical Virology

摘　　要：目的　以基因重组干扰素治疗急性乙型肝炎病人，观察其减少急性乙肝转慢率的效果。方法　用基因重组α干扰素（３００ 万Ｕ，肌内注射，隔日１ 次，１２ 周为一个疗程） 治疗１９ 名急性乙肝病人，对治疗后未产生抗ＨＢｓ 者，加用乙肝疫苗（３０ μｇ，肌内注射，每周注射１ 次，连用３ 周）；对照组为病情相似的１５ 例病人，服用一般保肝药物。结果　治疗组１８ 例（９５－０％ ，１８１９）ＨＢｓＡｇ 阴转，但均未产生抗ＨＢｓ，再用乙肝疫苗后，１７ 例（９４－０％ ，１７１９） 产生抗ＨＢｓ。２４～２４０ 周随访期间，１８ 例ＨＢｓＡｇ 阴转者无复发；１ 例ＨＢｓＡｇ 未阴转者，至随访结束时仍为阳性。对照组８ 例（５３－０ ％ ，８１５）ＨＢｓＡｇ 阴转，同时，８７－５ ％（７８）的病例产生抗ＨＢｓ，另７ 例ＨＢｓＡｇ 未阴转者，在２４ ～２４０ 周的随访期间，仅１ 例ＨＢｓＡｇ阴转，余６ 例ＨＢｓＡｇ 持续阳性。结论　对于急性乙型肝炎发病８ 周后ＨＢｓＡｇ 仍未阴转者，采用干扰素合用乙肝疫苗，对防止转慢及ＨＢｓＡｇ 阴转后抗ＨＢｓObjective In patients whose HBsAg are still positive after 8 weeks of acute hepatitis B attack, the chronic rate will increase. We try to treat them with IFN for reducing the rate of chronicity.Methods 19 patients were injected with rIFN α 3MU, q.o.d.for 12 weeks(treatment group), those who didn′t have anti HBs response after treatment were vaccinated with hepatitis B vaccine(30 μg, im, once weekly for 3 weeks); 15 patients received common therapy except rIFN α(control group). Results HBsAg negative seroconversion rate was 95.0%(18/19) in treatment group and 53.0%(8/15) in control group( P <0.05). No one responsed for anti HBs in 18 HBsAg negatively converted patients in treatment group, but in control group 87.5% of HBsAg negatively converted patients developed anti HBs ( P <0.001). Vaccinating the patients of treatment group, who didn′t developed anti HBs, with hepatitis B vaccine, 94.0% of them developed anti HBs. After 24 to 240 week follow up, no one relapsed in treatment group, in control group 8 HBsAg negative patients didn′t replase, 6 out of 7 HBsAg positive patients were still positive at the termination and follow up.Conclusion The therapy with rIFN α can reduce the chronic rate in the patients with acute HBV infection.

关 键 词：急性 乙型肝炎 基因重组干扰素 血源性乙肝疫苗 

分 类 号：R512.620.5[医药卫生—内科学]